Codon Devices Signs Distribution Agreement with Open Biosystems

Codon Devices, Inc., the Constructive Biology Company™, has announced that it has entered into an agreement in which Open Biosystems will distribute Codon Devices’ gene synthesis offering in North America.

Central to its vision of Constructive Biology™, Codon Devices is driving wide-spread adoption of synthetic genes. To date, the Company has maintained a minimum order threshold and thus access to its industrial-scale BioFAB™ platform has been restricted to researchers with large-scale requirements.

Under the terms of the agreement, Open Biosystems will sell and distribute Codon Devices’ gene synthesis offering to researchers with needs that fall below Codon’s minimum order threshold. The partnership will enable a wide range of new customers to utilize gene synthesis in their research.

“Through aggressive investments in its BioFAB™ platform, Codon Devices has moved quickly to industrialize synthetic biology and become a world leader in gene synthesis,” said Brian Pollock, Chief Executive Officer, Open Biosystems. “We are delighted to provide our customers with a new product offering that is clearly revolutionizing how life science research is conducted.”

RELATED ARTICLES

Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, researchers report they have discovered a mechanism of resistance to a treatment they’d identified as promising.